#AskDrDurie

Learn about the latest myeloma research. Get a front row seat at the most critical medical meetings. Watch Dr. Brian Durie, IMF Chairman, address issues that are important to the entire myeloma community. IMF TV brings it all to you.

Aug
17
Has Minimal Residual Disease (MRD) testing been approved by the FDA yet?
In this week’s video, Dr. Brian GM Durie explains that the FDA will soon consider MRD-testing as a surrogate endpoint for both newly diagnosed and relapsed myeloma patients. BOTTOM LINE: ​ It is very(...)
Aug
10
Are there myeloma clinics or specialists who focus on “high-risk” myeloma patients?
In this week’s video, Dr. Brian GM Durie explains why there is no precise treatment protocol for “high-risk” myeloma patients. BOTTOM LINE: ​ Get a second opinion at a myeloma center if your myeloma(...)
Aug
03
How many times can a myeloma patient undergo an autologous stem cell transplant?
In this week’s video, Dr. Brian GM Durie explains when and if a relapsed myeloma patient should undergo a second ASCT. BOTTOM LINE: ​ If the first remission after ASCT was at least 18 months to 2(...)
Jul
27
How soon will new “immune therapies” become mainstream?
In this week’s video, Dr. Brian GM Durie discusses the pros and cons of newer “immune therapies,” including monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and CAR-T cells.(...)
Jul
20
Are routine skeletal survey X-rays still recommended?
In this week’s video, Dr. Brian GM Durie explains why a baseline skeletal survey may be helpful, but more sensitive imaging is more precise. BOTTOM LINE: Rather than skeletal surveys, opt for MRI, CT(...)
Jun
29
Is MGUS always asymptomatic?
In this week’s video, Dr. Brian Durie explains that even though MGUS is benign, some MGUS patients may develop symptoms due to the presence of abnormal monoclonal protein in the blood.